Hepatitis C, Chronic
Conditions
Keywords
Hepatitis C, Chronic, TMC435, Hepatitis C, Hepatitis C virus, Interferon Alfa-2b, Ribavirin, Viral ribonucleic acid
Brief summary
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or treatment-experienced (prior relapser or non-responder to Interferon-based therapy) in Japan.
Detailed description
This is an open-label study (all people involved know the identity of the intervention) to evaluate the efficacy and safety of TMC435 (also referred to as jnj-38733214-aaa) in combination with the standard of care therapy (SoC: peginterferon \[pegIFN\] alfa-2b and ribavirin) in adult, genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive (never received treatment for HCV), prior relapsers (relapsed after previous interferon \[IFN\]-based therapy), or non-responders (failed to respond to previous IFN-based therapy) in Japan. The study objective is to evaluate the efficacy, safety, and pharmacokinetics of TMC435. A sufficient number of participants who are treatment-naive, prior relapsers to treatment with IFN-based therapy, and prior non-responders to treatment with IFN-based therapy will be enrolled and assigned to 1 of 3 panels (referred to as treatment groups). Participants who are treatment-naive or prior relapsers to IFN-based therapy will receive 12 weeks of treatment with TMC435 (100 mg) once daily with pegIFN alfa-2b and ribavirin (PR) followed by an additional 12 or 24 weeks of treatment with PR. Participants who are non-responders to IFN-based therapy will receive 12 weeks of treatment with TMC435 (100 mg) once daily with PR followed by an additional 36 weeks of treatment with PR. TMC435 is a 100-mg capsule and will be taken orally by mouth. The SoC treatment will consist of Pegylated interferon (PegIFN alpha-2b) (1.5 mcg/kg) injected with a syringe subcutaneously (under the skin) once weekly and ribavirin 200-mg capsules (daily dose: 600-1000 mg based on body weight) taken orally by mouth 2 times a day after meals for 24 or 48 weeks.
Interventions
DRUGTMC435
100 mg capsule taken by mouth once daily for 12 weeks
DRUGPeginterferon alfa-2b (pegIFN alfa-2b)
PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
DRUGRibavirin (RBV)
The dose of RBV given will be based on body weight. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Sponsors
Janssen Pharmaceutical K.K.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient must have chronic genotype 1 HCV infection with HCV RNA level \>= 5.0 log10 IU/mL * Patient has never received treatment for HCV (treatment-naive), relapsed after previous IFN-based therapy (prior relapser) or failed to respond to previous IFN-based therapy (non-responder) * Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication.
Exclusion criteria
* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV) * Diagnosed with hepatic cirrhosis or hepatic failure * A medical condition which is a contraindication to peg-IFN or ribavirin therapy * History of, or any current medical condition, which could impact the safety of the patient in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) | Week 36 or 60 | The table below shows the percentage of participants in each treatment group with an SVR12 defined as participants with undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment (Week 24 or 48) who also had undetectable plasma HCV RNA 12 weeks after the last dose of treatment (Week 36 or 60). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24) | 24 weeks after the last dose of treatment (Week 48 or 72) | The table below shows the percentage of participants in each treatment group with a SVR24 defined as participants with undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment and at 24 weeks after the last dose of treatment (Week 48 or 72). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Weeks 4, 12, 24, 36, 48, 60, 72, and EOT (up to Week 48) | The table below shows the percentage of participants in each treatment group with undetectable HCV RNA less than 1.2 log10 IU/mL during treatment and at end of treatment (EOT). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Number of Participants With Viral Breakthrough | Up to 48 Weeks | The table below shows the number of participants in each treatment group who experienced viral breakthrough during the TMC435 treatment period. Viral breakthrough is defined as a confirmed increase of greater than 1 log10 IU/mL in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached or a confirmed value of plasma HCV RNA of greater than 2.0 log10 IU/mL in participants whose plasma HCV RNA level had previously been reported below 1.2 log10 IU/mL detectable or undetectable. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Number of Participants Demonstrating Viral Relapse | Up to 72 weeks | The table below shows the number of participants in each treatment group who demonstrated viral relapse, defined as having undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels at end of treatment (EOT \[Week 24 or 48\]) and detectable HCV RNA during follow-up or detectable HCV RNA at the time points of an assessment of sustained virologic response (SVR). The number of participants analyzed in each treatment group below are those with undetectable HCV RNA levels at EOT and with at least one follow-up HCV RNA measurement. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT) | Up to Week 48 | The table below shows the number of participants in each treatment group with abnormal ALT levels at Baseline who achieved normalization of ALT levels defined as having an ALT value less than or equal to the Upper Limit of Normality (ie, 40 IU/mL) at EOT. At Baseline, 15 treatment-naïve participants, 13 prior relapsers, and 13 prior non-responders had abnormal ALT levels at Baseline. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 3, Day 7 and Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 36, 48, 60, 72, EOT (up to Week 24 or 48), follow-up (FU) Week 4, 12, and 24 | The table below shows the percentage of participants in each treatment group with greater than or equal to 2 log10 IU/mL drop from baseline in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at each time point during treatment and post-treatment follow-up. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24 | Week 24 or 48 | The table below shows the percentage of participants in each treatment group who met RGT criteria (ie, who had plasma levels of hepatitis C virus ribonucleic acid \[HCV RNA\] \<1.2 log10 IU/mL detectable/undetectable at Week 4 and \<1.2 log 10 IU/mL undetectable at Week 12) and completed treatment with PegIFNα-2b and RBV at Week 24. Participants in the TMC435 Treatment-Naïve and TMC435 Prior Relapser treatment groups not meeting RGT criteria continued treatment with PegIFNα-2a and RBV to Week 48 (does not apply to the TMC435 Non-responder treatment group because the specified treatment duration was 48 weeks and RGT criteria was not assessed at Week 24). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h) | Overall (Up to Week 12) | The table below shows the median (range) AUC24h values for TMC435 for all participants in each TMC435 treatment group who received TMC435 for up to 12 weeks. Overall is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
| Plasma Concentrations of TMC435 | Overall (Up to Week 12) | The table below shows the median (range) TMC435 predose plasma concentrations (C0h) and maximum concentration (Cmax) values for participants in each treatment group. Overall is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats). |
Countries
Japan
Participant flow
Recruitment details
The study was conducted between 01-Apr-2011 to 20-Nov-2012 and recruited participants with chronic Hepatitis C Virus (HCV) infection from 14 study centers in Japan. A total of 79 participants with chronic genotype 1 HCV infection were randomized and started treatment; 65 completed the study.
Pre-assignment details
Participants with genotype 1 hepatitis C virus (HCV) infection who were treatment-naïve or treatment-experienced (prior relapsers or nonresponders to interferon-based therapy) were assigned to 1 of 3 groups and received TMC435 100 mg/day for 12 weeks coadministered with PegIFNa-2b + ribavirin until Week 24 or Week 48.
Participants by arm
| Arm | Count |
|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 Participants received TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment was to be stopped at Week 24 in participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants continued PR until Week 48. | 24 |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 Participants received TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was to be stopped at Week 24 in participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants continued PR until Week 48. | 29 |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 Participants received TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48. | 26 |
| Total | 79 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Other | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 6 |
Baseline characteristics
| Characteristic | Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | Total |
|---|---|---|---|---|
| Age, Continuous | 60 years | 60 years | 53 years | 60 years |
| Sex: Female, Male Female | 16 Participants | 13 Participants | 13 Participants | 42 Participants |
| Sex: Female, Male Male | 8 Participants | 16 Participants | 13 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 24 / 24 | 29 / 29 | 26 / 26 |
| serious Total, serious adverse events | 1 / 24 | 0 / 29 | 1 / 26 |
Outcome results
Primary
Plasma Concentrations of TMC435
The table below shows the median (range) TMC435 predose plasma concentrations (C0h) and maximum concentration (Cmax) values for participants in each treatment group. Overall is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Overall (Up to Week 12)
Population: Pharmacokinetic (PK) analysis was performed in the PK population, defined as all participants from whom sparse blood samples were drawn and who received at least 1 dose of study medication.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | Plasma Concentrations of TMC435 | Cmax | 2304 ng/mL |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | Plasma Concentrations of TMC435 | C0h | 735 ng/mL |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | Plasma Concentrations of TMC435 | C0h | 2015 ng/mL |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | Plasma Concentrations of TMC435 | Cmax | 3643 ng/mL |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | Plasma Concentrations of TMC435 | Cmax | 2521 ng/mL |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | Plasma Concentrations of TMC435 | C0h | 921 ng/mL |
Primary
The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)
The table below shows the median (range) AUC24h values for TMC435 for all participants in each TMC435 treatment group who received TMC435 for up to 12 weeks. Overall is the median exposure estimate using all available data for each participant in the study. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Overall (Up to Week 12)
Population: Pharmacokinetic (PK) analysis was performed in the PK population, defined as all participants from whom sparse blood samples were drawn and who received at least 1 dose of study medication.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h) | 35448 ng·h/mL |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h) | 68130 ng·h/mL |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h) | 40645 ng·h/mL |
Primary
The Number of Participants Demonstrating Viral Relapse
The table below shows the number of participants in each treatment group who demonstrated viral relapse, defined as having undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels at end of treatment (EOT \[Week 24 or 48\]) and detectable HCV RNA during follow-up or detectable HCV RNA at the time points of an assessment of sustained virologic response (SVR). The number of participants analyzed in each treatment group below are those with undetectable HCV RNA levels at EOT and with at least one follow-up HCV RNA measurement. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Up to 72 weeks
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants Demonstrating Viral Relapse | 2 Participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants Demonstrating Viral Relapse | 1 Participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Number of Participants Demonstrating Viral Relapse | 4 Participants |
Primary
The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)
The table below shows the number of participants in each treatment group with abnormal ALT levels at Baseline who achieved normalization of ALT levels defined as having an ALT value less than or equal to the Upper Limit of Normality (ie, 40 IU/mL) at EOT. At Baseline, 15 treatment-naïve participants, 13 prior relapsers, and 13 prior non-responders had abnormal ALT levels at Baseline. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Up to Week 48
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT) | 13 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT) | 8 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT) | 8 Percentage of participants |
Primary
The Number of Participants With Viral Breakthrough
The table below shows the number of participants in each treatment group who experienced viral breakthrough during the TMC435 treatment period. Viral breakthrough is defined as a confirmed increase of greater than 1 log10 IU/mL in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached or a confirmed value of plasma HCV RNA of greater than 2.0 log10 IU/mL in participants whose plasma HCV RNA level had previously been reported below 1.2 log10 IU/mL detectable or undetectable. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Up to 48 Weeks
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants With Viral Breakthrough | 0 Participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Number of Participants With Viral Breakthrough | 0 Participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Number of Participants With Viral Breakthrough | 2 Participants |
Primary
The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up
The table below shows the percentage of participants in each treatment group with greater than or equal to 2 log10 IU/mL drop from baseline in plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at each time point during treatment and post-treatment follow-up. NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Day 3, Day 7 and Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 36, 48, 60, 72, EOT (up to Week 24 or 48), follow-up (FU) Week 4, 12, and 24
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 16 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 3 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 3 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 20 | 95.8 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 24 | 91.7 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 48 | 83.3 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 24 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 4 | 95.8 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 36 | 87.5 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 28 | 91.7 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 4 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 2 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | EOT | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 8 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 7 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 72 | 91.7 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 12 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 12 | 91.7 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 60 | 91.7 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 48 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 3 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 2 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 3 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 4 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 8 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 12 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 16 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 20 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 24 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 28 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 36 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 60 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 72 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | EOT | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 4 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 12 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 24 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 7 | 100 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 3 | 88.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 60 | 42.3 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 8 | 92.3 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 12 | 42.3 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 72 | 38.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 4 | 96.2 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Day 7 | 100 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | EOT | 80.8 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 3 | 96.2 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 24 | 38.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | FU Week 4 | 46.2 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 28 | 69.2 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 24 | 73.1 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 2 | 100 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 36 | 65.4 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 20 | 76.9 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 16 | 76.9 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 48 | 61.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up | Week 12 | 84.6 Percentage of participants |
Primary
The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24
The table below shows the percentage of participants in each treatment group who met RGT criteria (ie, who had plasma levels of hepatitis C virus ribonucleic acid \[HCV RNA\] \<1.2 log10 IU/mL detectable/undetectable at Week 4 and \<1.2 log 10 IU/mL undetectable at Week 12) and completed treatment with PegIFNα-2b and RBV at Week 24. Participants in the TMC435 Treatment-Naïve and TMC435 Prior Relapser treatment groups not meeting RGT criteria continued treatment with PegIFNα-2a and RBV to Week 48 (does not apply to the TMC435 Non-responder treatment group because the specified treatment duration was 48 weeks and RGT criteria was not assessed at Week 24). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Week 24 or 48
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24 | 91.7 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24 | 96.6 Percentage of participants |
Primary
The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)
The table below shows the percentage of participants in each treatment group with an SVR12 defined as participants with undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment (Week 24 or 48) who also had undetectable plasma HCV RNA 12 weeks after the last dose of treatment (Week 36 or 60). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Week 36 or 60
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) | 91.7 Percentage of Participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) | 100.0 Percentage of Participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) | 38.5 Percentage of Participants |
Primary
The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)
The table below shows the percentage of participants in each treatment group with a SVR24 defined as participants with undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) at the end of treatment and at 24 weeks after the last dose of treatment (Week 48 or 72). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: 24 weeks after the last dose of treatment (Week 48 or 72)
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24) | 91.7 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24) | 96.6 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24) | 38.5 Percentage of participants |
Primary
The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment
The table below shows the percentage of participants in each treatment group with undetectable HCV RNA less than 1.2 log10 IU/mL during treatment and at end of treatment (EOT). NOTE: All outcome measures reported in this study are Exploratory; not Primary as indicated (refer to Limits and Caveats).
Time frame: Weeks 4, 12, 24, 36, 48, 60, 72, and EOT (up to Week 48)
Population: The Full Analysis Set (FAS) consisted of all participants who received at least one dose of study drug during the study except for those who did not meet the major eligibility criteria for the study and participants who did not have efficacy data available after treatment with study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 24 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 12 | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 48 | 83.3 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 36 | 87.5 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | EOT | 100 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 60 | 91.7 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 4 | 79.2 Percentage of participants |
| Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 72 | 91.7 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 4 | 86.2 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 72 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | EOT | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 24 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 36 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 48 | 96.6 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 12 | 100 Percentage of participants |
| Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 60 | 96.6 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 24 | 65.4 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 4 | 57.7 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 12 | 76.9 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 36 | 57.7 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 48 | 53.8 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 60 | 38.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | Week 72 | 38.5 Percentage of participants |
| Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 | The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment | EOT | 57.7 Percentage of participants |